期刊
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL
卷 97, 期 4, 页码 568-571出版社
FERRATA STORTI FOUNDATION
DOI: 10.3324/haematol.2011.054064
关键词
CD20; BCP-ALL; Philadelphia negative; minimal residual disease; molecular
类别
资金
- Istituto Toscano Tumori
- Regione Toscana
- Ente Cassa di Risparmio di Firenze
- AIL Bergamo (Sezione Paolo Belli)
The prognostic significance of CD20 expression in acute lymphoblastic leukemia has been investigated in children and adults but is still a subject of debate. The aim of our study was to correlate CD20 expression with clinical-biological characteristics and outcome in 172 Philadelphia chromosome negative patients prospectively treated in a multicenter trial introducing the molecular evaluation of minimal residual disease for therapeutic purposes. We considered 20% as the threshold for CD20 positivity. Complete remission rate, minimal residual disease negativity rate at weeks 10, 16 and 22, and disease-free and overall survival were similar among CD20-positive and -negative patients, even considering minimal residual disease results and related therapeutic choices. Our study failed to demonstrate any prognostic significance for CD20 expression in Philadelphia chromosome negative acute lymphoblastic leukemia. This conclusion is supported for the first time by a comparable minimal residual disease response rate among CD20-positive and -negative and positive patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据